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doi:10.1016/j.ejvs.2011.03.033Abstract Aims: The utility of fenestrated-endovascular aneurysm repair (FEVAR) remains
uncertain. This study examines the medium term outcomes of patients undergoing FEVAR
for asymptomatic juxtarenal abdominal aortic aneurysm (AAA).
Methods: Consecutive patients undergoing elective FEVAR for juxtarenal AAA at a single
tertiary centre were studied between October 2005 and March 2010. Patients were followed
up for at least six-months within a protocol including clinical examination, laboratory studies,
CT and duplex imaging, and abdominal radiographs. Outcomes were assessed in terms of
survival, target vessel patency and graft related complications.
Results: Twenty-nine patients were analysed on an intention to treat basis. There were 27 men
and two women of median (range) age 74 (54e86) years. Mean (SD) aneurysm diameter was 68
(7) mm. Median (range) ASA score was 3 (2e4). No procedures required conversion to an open
procedure, but one procedure was abandoned. Seventy-nine visceral vessels were perfused
through a fabric fenestration or scallop. All vessels remained patent at completion angiog-
raphy. No patients died within 30-days of surgery. During follow up there were four (14%)
deaths at a median (range) of 17 (8e21) months after aneurysm repair. None of these deaths
were aneurysm related. Eighteen (62%) patients suffered one or more graft related complica-
tions, of whom 11 (38%) required one or more early or late reintervention.
Conclusions: Fenestrated aortic endografts can be utilized safely in the management of juxtar-
enal AAA in patients at high-risk for open surgery. However, the rate of graft related compli-
cation and reintervention is high at medium term follow up.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.31 242 3622; fax: þ44 131 242 3617.
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Endovascular Aneurysm Repair (EVAR) has established itself
as an effective treatment in the management of asymp-
tomatic, large, infrarenal abdominal aortic aneurysm
(AAA).1,2 However, more than 50% of patients have aneu-
rysm morphology that is unsuitable for conventional endo-
vascular repair.3 Of these, a significant proportion will have
an inadequate length of normal infrarenal aorta above the
aneurysm within which to achieve a proximal seal, and
account for up to 15% of AAA.4 Fenestrated endovascular
aneurysm repair (FEVAR) was first described in 1999 as an
endoluminal solution for patients with an inadequate
infrarenal aortic neck.5 Fabric fenestrations of the endog-
raft, with or without bridging stents, permit perfusion of
visceral branch vessels while achieving a secure proximal
seal. Such devices are now commercially available and are
challenging the established indications for EVAR.
Although a large number of fenestrated endoprostheses
have been implanted into patients, there is a paucity of
evidence to support the use of FEVAR. In the absence of
randomised controlled trials, small cohort studies underpin
the existing evidence base. Existing reports are generally
from endovascular enthusiasts reporting favourable short-
term outcomes.6e10 The present series reports the medium
term outcomes from a single centre, with the specific aim
of highlighting the challenges faced in the implementation
of a fenestrated aortic endograft programme.
Patients and Methods
A single-centre, retrospective, observational cohort study
was performed at the Leicester Royal Infirmary, UK. This is
a high-volume tertiary referral vascular surgical service
performing, approximately, 100 conventional EVARs each
year. Consecutive patients undergoing attempted repair of
an intact juxtarenal or suprarenal AAA with a fenestrated
endograft were accumulated over the period October
2005eJune 2010 and studied on an intention to treat basis.
Patients were selected for FEVAR on the basis of a jux-
tarenal AAA of at least 55 mm in diameter, with a proximal
neck too short for standard EVAR, but otherwise suitable
anatomy for EVAR together with unsuitability for open
aneurysm repair. Patients were deemed unsuitable for open
surgery on the basis of co-morbidities or previous abdom-
inal surgery with an abdomen too hostile for further lapa-
rotomy. Patients were classified using the American Society
of Anaesthesiologists (ASA) guidelines.
Preoperative high-resolution computed tomography (CT)
scans for all patients, and angiography obtained at the
physician’s discretion, were used to determine if the
aneurysm morphology was suitable for FEVAR. Customised
fenestrated devices based on the Cook Zenith system
(William A. Cook Australia, Ltd., Brisbane, Australia) were
designed on multiplanar reconstructions and centreline of
flow calculations derived from CT scans. Diameters and
lengths of the aorta and iliac arteries, and visceral vessel
morphology were used to measure the relative positions of
visceral vessels to match the fenestrations in a similar
manner to prior publications.11 Small (6  8 mm), large
(>8 mm), or scalloped (located at the uppermost portion offabric) fenestrations were included as options for the
device design. All procedures were performed under
general anaesthesia in a conventional operating room with
mobile imaging equipment. Completion angiography was
used to ensure freedom from endoleak, vessel patency and
aneurysm exclusion. The first four cases in the series were
undertaken under the mentorship of the multidisciplinary
team from the Royal Liverpool Hospital, UK.6
Patients were followed up for at least six-months within
a protocol which included clinical examination, laboratory
studies, CT and duplex imaging, and abdominal radio-
graphs. The current surveillance protocol entails antero-
posterior and lateral plain X-rays, duplex ultrasound and CT
aortography prior to discharge. Duplex ultrasound and CT
scan at 3 months, plain X-rays and duplex ultrasound at
6 months and plain X-rays, duplex ultrasound and CT scan at
12 months and yearly thereafter. Diagnostic angiography
was utilized selectively. Outcomes were assessed in terms
of survival, target vessel patency, graft related complica-
tions and reintervention, in accordance with SVS reporting
standards for EVAR.12 An increase in aneurysm sac size of
>5 mm was regarded as a complication.
Results
Patients
Twenty-nine patients were included within an intention to
treat protocol. Therewere 27menand twowomenofmedian
(range) age 74 (54e86) years. The mean (SD) aneurysm
diameter was 68 (7) mm and the median (range) ASA score
was 3 (2e4). Three patients had undergone a failed attempt
at open AAA repair at another centre prior to FEVAR. One
patient was already established on haemodialysis prior to
intervention. Patient comorbidity is shown in Table 1.
Endografts
A three-component system was utilized in all but one of the
patients. In the remaining patient, an aorto uni-iliac system
and contralateral iliac occluder device were used due to
access difficulties. Seventy-nine visceral vessels were inten-
ded to be perfused through a fenestration or scallop,
including 52 renal arteries, 25 superior mesenteric arteries
(SMA)and2 coeliac arteries. Themost commonconfiguration,
two fenestrations for the renal arteries and a scallop fenes-
tration for the SMA, was used in 19 patients. Three patients
had a single renal fenestration, two required one renal
fenestration with two scallops for the remaining renal and
SMA, two required a single renal fenestration and a scallop for
the other renal and one patient only needed a single scallop
for a single renal artery. Two patients needed grafts with four
fenestrations to also include the coeliac artery. None of the
grafts incorporated an accessory renal artery.
Procedural details
None of the procedures required immediate conversion to
an open repair. However, five (18%) patients suffered
an intraoperative complication. In one patient with
Table 1 Comorbidity amongst 29 patients.
Comorbidity Number of patients
Smoker/COPD 21 (72%)
Hypertension 15 (52%)
Ischaemic Heart Disease
(MI or Angina)
13 (45%)
Hostile abdomen/Stoma 4 (14%)
Chronic Renal Failure
(eGFR < 60)
3 (10%)
Cardiac failure 3 (10%)
Cerebrovascular disease 2 (10%)
Table 2 Causes of death and time after FEVAR in four
patients.
Cause of death Time (months)
Stroke 22
Multiorgan failure following
strangulated hernia
18
Pneumonia 15
Chronic renal failure 8
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completely as the mainbody of the endograft could not be
manipulated to achieve correct orientation within the
aorta. One patient was found to have an incorrect main-
body graft size and had to be rescheduled for completion of
FEVAR two weeks later. In a further patient, the imaging
equipment failed intraoperatively, and again this patient
had to be brought back for completion of FEVAR four days
later.
All but two of 49 fenestrations were reinforced with
a stent, of which 29 were covered stents and 18 uncovered.
All 47 stents were in renal arteries apart from one patient
who had covered stents placed in the SMA and coeliac artery,
and one patient who had a single uncovered SMA stent.
One patient suffered a renal artery perforation that
required placement of a covered stent, and another patient
had an acutely ischaemic lower limb due to common
femoral artery thrombosis in a chronically diseased vessel.
This patient required a common femoral thromboendar-
terectomy and patch closure to achieve revascularisation.
Apart from the patient inwhomFEVARwas abandoned, all
other patients had successful aneurysm exclusion alongside
target vessel preservation on completion angiography.
Early postoperative outcomes
There were no deaths in-hospital or within 30-days of
aneurysm repair. Eight patients were monitored in the
intensive care unit postoperatively. All but one were dis-
charged to the ward after one day, while the remaining
patient stayed for two days. No patients required new
postoperative renal replacement therapy. Median (range)
length of hospital stay was three (1e12) days. The patient
in whom FEVAR was unsuccessful was discharged after
a day. Only one patient suffered an early postoperative
graft related complication. In this patient, a covered renal
stent was found to have occluded on the first postoperative
day. Repeat renal angioplasty and stenting was performed
with recovery of renal perfusion.
Late outcomes
Median (range) length of follow up was 20 (7e62) months.
Therewere four deaths during follow up, at amedian (range)
of 17 (8e22) months after FEVAR. None of these deaths
were aneurysm related. The patient with preoperative hae-
modialysis dependent renal failure died from complicationsof renal failure eight months after surgery. Causes of death
and time from surgery are shown in Table 2.
Fourteen (48%) patients suffered one or more graft
related complications followingdischarge fromhospital. Two
of these patients had already had a perioperative or early
postoperative complication. One patient’s SMA and another
patient’s renal artery thrombosed during follow-up. Both
case were asymptomatic. The most common complications
were renal stent fracture, stenosis or migration. Of the 29
covered stents, there were three renal stent migrations and
three stent stenoses. Of the 18 uncovered stents, there were
four stent fractures with stenosis, two stent fractures with
vessel thrombosis and two stent stenoses. Within the series,
there are six renal stent stenoses in five patients that are
being managed expectantly.
Four (14%) patients had an increase in their aneurysm
sac size >5 mm during follow up. One patient had types I,
II and III endoleaks that have required intervention; the
type III endoleaks needed renal stent angioplasty on one
side and redo renal stenting on the other, the type I
endoleak was treated with the liquid embolisation agent
Onyx (Micro Therapeutics, Inc., CA, USA). Another patient
had a type II endoleak treated with inferior mesenteric
artery embolisation. A further patient has a probable type I
endoleak and is awaiting intervention. The final patient had
an indeterminate endoleak, but was found to be too
frail for further investigation or reintervention, and was
managed expectantly, eventually dying from pneumonia
12 months after diagnosis. There were two other type II and
a type III endoleak without evidence of sac expansion.
Types of complication are listed in Table 3.
Nine (32%) patients required one or more late reinter-
ventions at a median (range) of seven (1e12) months. Types
of reintervention are listed in Table 4. One patient in the
series has required three reinterventions to treat type III
endoleaks at each renal stent and a type I endoleak. Two
patients have needed two reinterventions; one a renal stent
angioplasty and iliac limb extension and the other has
required repeated restenting of a fractured uncovered renal
stent.Discussion
Fenestrated endovascular aneurysm repair represents an
attractive option for patients with aortic aneurysm
morphology that is unsuitable for conventional EVAR.
Feasibility has been demonstrated clearly and uptake of the
technique has been compelling, with more than 2000 pros-
theses inserted worldwide.9 However, the evidence base to
support FEVAR is less persuasive at present. It is noteworthy
Table 3 Fourteen patients with one or more late graft
related complication.
Complication Number of patients
Renal stent fracture/stenosis
(unilateral or bilateral)
9
Iliac limb stenosis/occlusion
(unilateral or bilateral)
3
Target vessel loss (SMA x1, Renal x1) 2
Type III endoleak e junctional
(unilateral or bilateral)
2
Type II endoleak with sac expansion 2
Type I endoleak 2
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able to account for less than 25% of the devices that have
been used.13 Although the existing observational cohort
studies stem from esteemed endovascular centres, that
have been early adopters of the technology, the nature of
publication bias may result in an unrealistic picture. To
permit the rational, and evidence based, development of
FEVAR as a therapeutic solution for juxtarenal AAA, there is
a need for multicentre outcome data to be standardised,
and collated centrally for meaningful analysis. Such
a collaborative endeavour is already in place in the form of
the GLOBAL collaborators on Advanced Stent-graft Tech-
niques for Aneurysm Repair (GLOBALSTAR) project, and
support of this initiative must be encouraged.14
The present data reports a non-randomised series of
patients with large asymptomatic juxtarenal AAA with
unfavourable comorbidity for open repair selected for
FEVAR. Careful patient selection governed the series, which
represents all patients ever treated with a fenestrated
endograft from this centre. It therefore reflects the chal-
lenges experienced during the learning curve and the lessons
learnt.
Procedural complications in the form of problems of
equipment or device complications arose in three patients.
The most salutary lesson stemmed from the patient in
whom the endograft could not be adequately orientated.
This patient had undergone a successful trial passage of
a Lunderqvist stiff wire prior to surgery and been deemed
suitable for FEVAR. However, the calibre of the fenestrated
endograft resulted in an inability to manoeuvre the device
within the aorta. The procedural vulnerability, due to the
bespoke nature of the endograft, was highlighted by the
patient who was found to have been supplied with an
incorrect prosthesis. This complication arose due toTable 4 Ninepatientswithoneormore late reinterventions.
Type of reintervention Number of patients
Renal stent angioplasty 4
Redo renal stenting 3
Iliac limb extension 2
Onyx injection for Type I
endoleak
1
Inferior mesenteric artery
embolisation
1
Attempted SMA angioplasty 1a miscalculation during endograft sizing from a CT scan
imported from another hospital. Furthermore, it is neces-
sary to have a broad range of ancillary equipment in the
form of wires, catheters and stents to cater for unforeseen
events like vessel perforation, stent misalignment or chal-
lenging catheterisation. This factor undoubtedly influenced
the 100% target vessel patency in the patients who had an
endograft deployed. A policy of aiming to stent all fenes-
trations has been advocated by other centres, and
contributes to target vessel preservation.8 A trend towards
more complications in uncovered stents was observed
within these data. This has resulted in a move towards the
routine use of covered stents.
These data are notable by virtue of the freedom from
significant early postoperative complications. Apart from
a renal stent thrombosis, no major adverse events were
encountered. In particular, no patient experienced a new
requirement for renal replacement therapy. The finding
that significant nephropathy can be avoided has also been
confirmed by many other series.7e9 This feature is likely
to be due to the multifactorial influence of stringent
patient selection, careful operative technique and peri-
operative care.
The primary aim of aneurysm repair is to prevent death
from aortic rupture. This aim has been accomplished in all
patients from this series at medium term follow-up, and
fenestrated endografting can be affirmed as an effective
treatment of juxtarenal AAA. This is further emphasised by
virtue of all but four patients demonstrating shrinkage of
the aneurysm sac. Although no perioperative deaths were
encountered in this small series, reported perioperative
mortality rates after FEVAR are in the order of 1e4%.7e9,12
Mortality rates should be expected to be greater than the
1.4% seen in the EVAR-1 randomised controlled trial, in the
context of a procedure of greater technical complexity
undertaken on frailer patients.3 Patients in this series were
unfit as reflected by the median ASA score of 3. This chronic
ill-health burden is reflected in the late mortality rate of
14% within two years of AAA repair. It is, however,
comparable with other series where death, during similar
periods of follow-up, has ranged between 9 and 22%.7e9
Selection for treatment must balance the risk of death
from rupture against the predicted surgical mortality. It is
conspicuous that in the largest reported series of FEVAR,
half of the patients had AAA of 45e55 mm diameter.9 Such
patients could be anticipated to have an annual rupture risk
of less than 1% compared to the reported 30-day mortality
rate of 2% after FEVAR.9,15
Themost notable feature of the present data is the rate of
reintervention required during medium-term follow up. It is
acknowledged that the rate of complication in the current
data, in part, must reflect an unavoidable learning curve
associated with a new procedure of challenging complexity.
However, there appears to be an inherently high rate of
complications associated with the technique that likely
relates to the mechanical stresses on branch vessels stents
constrained by a relatively fixed aortic endograft.
Systematic review has reported a reintervention rate
of 15% after FEVAR.12 In contrast, the present data have
shown a reintervention rate of 38%. Reasons for the
discrepancy are unclear. Given that conventional EVAR
carries a 20% reintervention rate at four years, it may be that
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Patients in the present series had a median AAA diameter of
60 mm, greater than some other reported series. Larger
aneurysm diameter has been shown to be a predictor of graft
related complication and reintervention after EVAR, and this
is likely to hold true for FEVAR.17 The need for reintervention
will largely be influenced by the stringency of follow-up and
imaging protocols. It is interesting that all patients who
needed reintervention, were treated within the first year
after aneurysm repair. Again, this mirrors data from
conventional EVAR.17 In contrast, FEVAR is likely to mandate
a more enduring and detailed follow-up protocol to ensure
target vessel patency. The current surveillance protocol,
although intensive, appears effective in the diagnosis of
branch vessel compromise. In particular, duplex ultrasound
and plain X-rays, in combination, provide valuable informa-
tion on flow dynamics within and beyond target vessels, and
stent integrity and positioning respectively.
In conclusion, these data add to the accumulating
evidence to support FEVAR as a feasible, safe and effective
treatment in the management of high-risk patients with
juxtarenal aortic aneurysm. However, the rate of graft
related complications and need for reintervention is higher
than previously reported at medium term follow-up. Graft
durability remains uncertain and longer-term follow-up
data are needed.
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